HC Wainwright Issues Negative Forecast for PLX Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Analysts at HC Wainwright reduced their Q1 2026 earnings per share estimates for Protalix BioTherapeutics in a report released on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.01) per share for the quarter, down from their prior forecast of $0.04. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q2 2026 earnings at $0.27 EPS, Q3 2026 earnings at ($0.01) EPS and FY2027 earnings at $0.14 EPS.

Protalix BioTherapeutics Price Performance

Shares of NYSE:PLX opened at $2.13 on Monday. The company has a market capitalization of $171.62 million, a price-to-earnings ratio of -16.38 and a beta of -0.26. The business’s 50-day moving average is $2.61 and its 200-day moving average is $2.21. Protalix BioTherapeutics has a 1 year low of $1.32 and a 1 year high of $3.19.

Institutional Trading of Protalix BioTherapeutics

Several hedge funds have recently bought and sold shares of PLX. Invesco Ltd. boosted its position in Protalix BioTherapeutics by 12.4% in the fourth quarter. Invesco Ltd. now owns 50,563 shares of the company’s stock worth $91,000 after purchasing an additional 5,560 shares during the last quarter. Main Street Financial Solutions LLC grew its stake in Protalix BioTherapeutics by 65.8% in the 4th quarter. Main Street Financial Solutions LLC now owns 214,100 shares of the company’s stock valued at $385,000 after purchasing an additional 85,000 shares during the period. Lazard Asset Management LLC purchased a new stake in shares of Protalix BioTherapeutics during the 4th quarter valued at $129,000. Barclays PLC raised its stake in shares of Protalix BioTherapeutics by 10.9% during the 4th quarter. Barclays PLC now owns 112,849 shares of the company’s stock worth $203,000 after purchasing an additional 11,051 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of Protalix BioTherapeutics during the 4th quarter worth $34,000. Institutional investors and hedge funds own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.